Musculoskeletal and joint disease

North and East Devon health care community shared care guidelines – musculoskeletal and joint disease

Click on the links below to access individual guidelines. 
Please see DMARDs (disease-modifying anti-rheumatic drugs) for overview of monitoring requirements for treatment of rheumatological conditions and inflammatory bowel disease:
DMARDs – overview of monitoring requirements for treatment of rheumatological conditions and inflammatory bowel disease (April 2012) Azathioprine for the treatment of rheumatological conditions (April 2011) Azathioprine for the treatment of rheumatological conditions – KEY CHANGES to updated guideline (April 2012) Ciclosporin - rheumatology (March 2008) Denosumab (Prolia®) for osteoporosis (November 2016) Gold Intramuscular injection (sodium aurothiomalate) for the treatment of rheumatoid arthritis (Feb 2011) Gold Intramuscular injection (sodium aurothiomalate) for the treatment of rheumatoid arthritis – KEY CHANGES to updated guideline (April 2012) Hydroxychloroquine for the treatment of rheumatoid arthritis and systemic lupus erythematosus (April 2011) Hydroxychloroquine for the treatment of rheumatoid arthritis and systemic lupus erythematosus – KEY CHANGES to updated guideline (April 2012) Leflunomide for the treatment of rheumatoid arthritis and psoriatic arthritis (April 2011) Leflunomide for the treatment of rheumatoid arthritis and psoriatic arthritis – KEY CHANGES to updated guideline (April 2012) Methotrexate for juvenile arthritis (July 2006) Methotrexate for the treatment of rheumatological and autoimmune diseases (April 2011) Methotrexate for the treatment of rheumatological and autoimmune diseases – KEY CHANGES to updated guideline (April 2012) Penicillamine for the treatment of rheumatoid arthritis (February 2011) Penicillamine for the treatment of rheumatoid arthritis – KEY CHANGES to updated guideline (April 2012) Sulfasalazine for the treatment of rheumatological conditions (April 2011) Sulfasalazine for the treatment of rheumatological conditions – KEY CHANGES to updated guideline (April 2012)

Rate this page